Clinical trial SYMPATICO
Phase 3 Study of Ibrutinib in Combination with Venetoclax in Subjects with Mantle Cell Lymphoma
| Cancers | |
|---|---|
| Organ | Lymphoma |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Pharmacyclics, Inc. |
| EudraCT Identifier | 2017-000129-12 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03112174 |
| Inclusion criteria | 2nd to 6th line / at least 1 measurable imaging lesion >=2,0cm /archived or fresh biopsy available / no prior treatment with BCL2 inhibitors |
| Last update |